An independent committee has recommended that Roche (RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."
The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.
Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.
Shares are -1.7% in Zurich. (PR)